Tag: patient education
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Six Facts About Clinical Research Participation for ALK-Positive Lung Cancer Patients
by Dr. Ken Culver, Executive Director and Medical Director, ALK Positive, Inc.
-
True or False: Test Your Knowledge of Clinical Trials
Clinical trials are often misunderstood. This short quiz explores common myths and facts about trials, helping patients better understand participation, safety, and the role research plays in improving outcomes for ALK-positive cancers.
-
ALKtALK: Break Through Cancer’s Jesse Boehm Returns to ALKtALK with information, insight, and hope.
Sunday, December 14th, Jesse Boehm returns to ALKtALK with an informative update on Break Through Cancer’s PowerRD 2 Cure ALK+ Lung Cancer TeamLab. If you’re hearing about Break Through Cancer for the first time, this is a perfect opportunity to learn about the radical collaboration powering this groundbreaking project. For those who have been following along, Zoom in to…
-
ALKtALK: Holiday Stress Health
Who: Dr. Karen Schurgin 📅 When: Sunday, December 7th, 7pm ET📺 Replay: Recording will be available on the ALK Positive YouTube channel Don’t miss this ALKtALK with Dr. Karen Schurgin @ 7pm ET She’s back with her signature blend of wit, wisdom, and honesty for a conversation many of us need right now: how to…
-
Living Both Sides of Lung Cancer: Dr. Ross Camidge Returns to ALKtALK
Dr. Ross Camidge, Director of Thoracic Oncology at the University of Colorado Cancer Center, has been a trusted voice and sought-after second opinion for lung cancer patients around the world for decades. He has spoken at ALK Positive Summits, appeared on multiple ALKtALKs, and serves on the ALK Positive Scientific Advisory Board- guiding and supporting…
-
ALKtALK: Dr. Angel Qin
Join the one and only Dr. Angel Qin, thoracic oncologist at the University of Michigan and member of the ALK Positive Scientific Advisory Board, this Sunday at 7 PM ET. We will take a deep dive into the new Gilteritinib trial, sponsored by Astellas Pharma Inc., and what this new trial could mean for the…
-
Medical Committee Update
Join us for ALKtALK with Shirish Gadgeel, MD, and gain a deeper understanding of the essential role chemotherapy plays in ALK-positive cancer care.
-
The wait is over— Season 6 of ALKtALK begins with Dr. Christine Lovly.
Join us for ALKtALK with Shirish Gadgeel, MD, and gain a deeper understanding of the essential role chemotherapy plays in ALK-positive cancer care.
-
Let’s talk meds, interactions, and whole-person care in thoracic oncology.Join ALKtALK for a discussion on Managing Meds & More: The Pharmacist’s Role in ALK+ Cancer
-
Dr. Shirish Gadgeel
Join us for ALKtALK with Shirish Gadgeel, MD, and gain a deeper understanding of the essential role chemotherapy plays in ALK-positive cancer care.
-
ALK patients with hight PD-L1 expression and immunotherapy
Many of our members are wondering if immunotherapy with current checkpoint inhibitors may be a good idea for them if they have been diagnosed with a high PD-L1 expression. Spoiler alert: it is a bad idea for most. Read on to find out why. Using immunotherapy with checkpoint inhibitors has invigorated the treatment and hopes…